Krystal Biotech (KRYS) Cash & Current Investments (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Cash & Current Investments data on file, last reported at $823.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 33.49% year-over-year to $823.4 million; the trailing twelve-month figure through Mar 2026 stood at $823.4 million (up 33.49% YoY), and the FY2025 full-year result was $827.8 million, up 38.54% from the prior year.
• Cash & Current Investments slipped to $823.4 million in Q1 2026, from $827.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $827.8 million in Q4 2025 to a low of $350.4 million in Q1 2023.
• A 5-year average of $560.0 million and a median of $559.6 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments dropped 19.38% in 2023 and soared 53.62% in 2024, its largest moves.
• Tracing KRYS's Cash & Current Investments over 5 years: stood at $379.2 million in 2022, then soared by 40.35% to $532.2 million in 2023, then gained by 12.28% to $597.5 million in 2024, then jumped by 38.54% to $827.8 million in 2025, then retreated by 0.53% to $823.4 million in 2026.
• Business Quant data shows KRYS's Cash & Current Investments at $823.4 million in Q1 2026, $827.8 million in Q4 2025, and $731.1 million in Q3 2025.